SCHEMBL2351289

SCHEMBL2351289

CCOC(=O)CCc1ccc(OCc2ccc(OCC)cc2)c(F)c1

nearest known ligand 0.53

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
FFAR1 O14842 10/20 0.53
PPARD Q03181 5/20 0.53
PPARG P37231 1/20 0.53
PPARA Q07869 1/20 0.53
CYP4F2 P78329 1/20 0.47
CYP4A11 Q02928 1/20 0.47
FFAR4 Q5NUL3 4/20 0.45
SLC5A1 P13866 1/20 0.45
SLC5A2 P31639 1/20 0.45
AKR1C3 P42330 2/20 0.43
APP P05067 1/20 0.42
RXRG P48443 1/20 0.42
MAOB P27338 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2353371 0.92 FFAR1 (0.52) FFAR1PPARDPPARGPPARACYP4F2
SCHEMBL2353360 0.89 FFAR1 (0.53) FFAR1PPARDPPARGPPARAFFAR4
SCHEMBL2350411 0.89 FFAR1 (0.53) FFAR1PPARDPPARGPPARACYP4F2
SCHEMBL2349909 0.89 FFAR4 (0.49) FFAR1PPARDPPARGPPARACYP4F2
SCHEMBL2355823 0.88 FFAR1 (0.57) FFAR1PPARDPPARGPPARAFFAR4
SCHEMBL2354856 0.86 FFAR4 (0.50) FFAR1PPARDPPARGPPARACYP4F2
SCHEMBL2350376 0.86 FFAR1 (0.48) FFAR1PPARDPPARGPPARACYP4F2
SCHEMBL2356175 0.84 FFAR1 (0.55) FFAR1PPARDPPARGPPARACYP4F2
SCHEMBL2353527 0.84 AKR1C3 (0.52) FFAR1CYP4F2CYP4A11FFAR4AKR1C3
SCHEMBL12394660 0.84 FFAR4 (0.60) FFAR1CYP4F2CYP4A11FFAR4AKR1C3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8008525-B2 For the 14273 peroxisome proliferator activated receptor; antidiabetic agents, hyperlipidemia, obesity or anorexia; receptor binding assay; drug screening kits TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-08-30 US disclosed
US-8008525-B2 For the 14273 peroxisome proliferator activated receptor; antidiabetic agents, hyperlipidemia, obesity or anorexia; receptor binding assay; drug screening kits TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-08-30 US disclosed
US-8008525-B2 For the 14273 peroxisome proliferator activated receptor; antidiabetic agents, hyperlipidemia, obesity or anorexia; receptor binding assay; drug screening kits TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-08-30 US disclosed
US-20080167378-A1 Receptor Function Regulation Agent TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-07-10 US disclosed
US-20080167378-A1 Receptor Function Regulation Agent TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-07-10 US disclosed
US-20080167378-A1 Receptor Function Regulation Agent TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-07-10 US disclosed
EP-1688138-A1 RECEPTOR FUNCTION REGULATING AGENT Takeda Pharmaceutical Company Limited (JP) 2006-08-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080167378-A1 Receptor Function Regulation Agent GPR119, INSR, GPR88 FFAR1 16/4885PPARD 316/4885PPARG 210/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.